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Matrix degradation by chondrocytes cultured in alginate: IL-1b
induces proteoglycan degradation and proMMP synthesis but does
not result in collagen degradation
By Bob Beekman, Nicole Verzijl, Jeroen A. D. M. de Roos and Johan M. TeKoppele
Gaubius Laboratory, TNO Prevention and Health, Dept. Vascular and Connective Tissue Research,
P.O. Box 2215, 2301 CE Leiden, The Netherlands
Summary
Objective: To determine the role of interleukin-1b (IL-1b) in the degradation of proteoglycans and collagen by articular
chondrocytes.
Design: Chondrocytes were cultured in alginate beads for 2 weeks to produce extracellular matrix, followed by the
addition of IL-1b for 1 or 2 days. Breakdown of extracellular matrix (with and without activation of pro-matrix
metalloproteinases (MMPs) by APMA) was monitored by release of glycosaminoglycans (GAG, proteoglycans) and
hydroxyproline (collagen) from the beads into the medium, and by the amount of damaged collagen in the bead. Levels
of (pro)MMPs in the beads were assayed by zymography and their activity was quantified fluorometrically.
Results: IL-1b induced a profound GAG release ( 0 80% after 2 days at 20 ng/ml IL-1b) that was both time and IL-1b
concentration dependent. Under these conditions no increase in collagen release or damaged collagen in the bead was
detected. Zymography demonstrated that the synthesis of a variety of proMMPs was induced by IL-1b, without a
detectable increase of MMP-activity as measured in the activity assay. After activation of the proMMPs by APMA,
a time and IL-1b concentration-dependent increase in MMP-activity was found, which resulted in almost complete
deterioration of collagen already after 18 h of incubation. In the presence of APMA, GAG release from IL-1b treated
beads was significantly increased from 24 to 31%.
Conclusions: Our data suggest that proteoglycan and collagen degradation are regulated through different
mechanisms: IL-1b induces the synthesis of active enzymes that degrade proteoglycans, such as ‘aggrecanase’, and
inactive proMMPs. Thus, IL-1b alone is not sufficient to result in collagen-degrading MMPs. Once activated, MMPs
may account for up to a quarter of the aggrecan degradation in this model.
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Introduction
Interleukin-1 (IL-1) is a cytokine alleged to play
a major role in cartilage destruction in arthritis
[1–6]. These processes include enhanced proteogly-
can degradation and upregulation of matrix
metalloproteinase (MMP) synthesis [7]. MMPs are
excreted as inactive proforms that are able to
degrade proteoglycans and the collagen network
in cartilage after proteolytic activation. Several
classes of MMPs exist (for reviews, see [8, 9]): the
collagenases MMP-1, -8 and -13 cleave triple
helical collagen type I, II and III, the gelatinases
(MMP-2 and -9) degrade non-triple helical collagen
(gelatin); active stromelysin (MMP-3) was shown
to activate proMMP-1, -8, -9 and -13 [10–13] and is
thought to be involved in the degradation of
proteoglycans [14, 15]. Recently, the role of MMP-3
in proteoglycan degradation has been overshad-
owed by ‘aggrecanase’, an as yet unidentified
proteinase that cleaves in the interglobular
domain of aggrecan between Glu373–Ala374 [16–19].
Upon IL-1 stimulation, proteoglycan degradation
in cartilage explants starts within 1 day at
relatively low concentrations of IL-1 [17, 20–22].
In contrast to the rapid degradation of proteo-
glycans, collagen release in nasal cartilage
explants occurs only after long time periods ( r 3
weeks) at relatively high levels of IL-1 (50 ng/ml)
[20, 23, 24]. However, maximal MMP-synthesis by
chondrocytes is observed within a few days in the
presence of IL-1 [25–27]. The long lag-time between
synthesis of MMPs and detectable MMP-mediated
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degradation of collagen, suggests a non-IL-1
mediated activation of MMPs (e.g., by other
factors or resulting from autoactivation). The
present study was designed to determine the role of
IL-1 in degradation of extracellular matrix upon
short-term ( R 2 days) exposure of chondrocytes to
IL-1 and in the absence of non-chondrocytic factors
which may be present in articular cartilage,
e.g., other catabolic cytokines or activating
proteinases originating from other cell types like
synoviocytes or inflammatory cells. For this
purpose, isolated bovine chondrocytes were
cultured in the alginate bead culture system,
in which they produce a cartilage-like matrix
[28, 29], before IL-1 treatment.
Method
cell isolation and culture
Chondrocytes from the metacarpophalangeal
joint of calves (12–14 months old, local slaughter-
house) were isolated by collagenase digestion
following established procedures [28, 30, 31]. Cells
were suspended in 1.2% alginate (Keltone LVCR,
Kelco, Chicago, U.S.A.) in 0.9% NaCl at a density
of 4 · 106 cells/ml, which was passed dropwise
through a 22 gauge needle into 102 mm CaCl2. After
10 min of polymerization, beads were washed in
0.9% NaCl (three times) and finally in Dulbecco’s
modified Eagle’s medium (DMEM)-glutamax
(Gibco-BRL) supplemented with 100 U/ml of
penicillin–streptomycin, 10% FCS (Gibco-BRL)
and 50 mg/ml ascorbic acid. The cells were cultured
at 10 beads per 0.5 ml medium (24 wells plate,
Costar) in a humid atmosphere of 5% CO2 in air at
37° C. The medium was refreshed twice weekly.
After 14 or 21 days of culture, the beads were
washed three times for 1 h with DMEM sup-
plemented with 0.05% human serum albumin
(HSA, Bloodbank, Amsterdam, The Netherlands)
and transferred to a fresh culture plate. Chondro-
cytes were stimulated with human recombinant
IL-1b (PeproTech, London, UK) for 24 or 48 h;
beads and media were stored separately at - 20° C
until analysis.
proteoglycan measurements
The amount of sulfated glycosaminoglycans
(GAGs) reflecting the amount of proteoglycans in
culture medium or alginate beads was determined
by the dimethyl methyleneblue method using a
commercial kit (Biocolor Ltd, Belfast, N. Ireland)
according to the instructions of the manufacturer.
Beads were digested for 2 h at 65° C in papain buffer
(126 mg/ml papain in 50 mm phosphate buffer pH
6.5, containing 2 mm l-cysteine and 2 mm EDTA
[32]) before the measurement. Culture media were
analyzed without papain digestion. Proteoglycan
degradation was expressed as the percentage of
GAG released into the medium.
collagen measurements
After two washes, once in 0.9% NaCl containing
10 mm CaCl2 and once in saline, beads were
hydrolyzed in 500 ml 6 n HCl per bead at 108° C for
24 h. An aliquot (50 ml) of the hydrolysate was
subjected to amino acid analysis, (see below) to
determine the collagen-specific amino acid
hydroxyproline. Alternatively, beads were digested
in papain buffer first (see above) and then
hydrolyzed.
The collagen content of culture medium was
determined by amino acid analysis after acid
hydrolysis (24 h at 108° C) of 100 ml of the medium
with 100 ml 12 m HCl. After drying of the
hydrolyzates under vacuum, the residue was
dissolved in 200 ml 0.1 m borate buffer (pH 9.5).
Primary amino acids were blocked by derivatiza-
tion with 25 ml 0.23 m o-phthaldialdehyde (Sigma,
St Louis, MO, U.S.A.) in acetone containing 0.23 m
b-mercaptoethanol (Merck, Darmstadt, Germany),
for 1 min at room temperature. After addition of
25 ml 0.45 m iodoacetamide (in acetone, reaction for
30 s) to remove excess b-mercaptoethanol, sec-
ondary amino acids (hydroxyproline and proline)
were derivatized with 50 ml 6 mm FMOC-Cl (Fluka,
Buchs, Switzerland) in acetone for 10 min [33,34].
Resulting samples were extracted twice with 750 ml
diethylether and thereafter the water phase was
diluted threefold in 0.1 m borate buffer (pH 8.0)
containing 25% (v/v) acetonitrile. High-perform-
ance liquid chromatography (HPLC) analysis was
performed as described earlier [35]. The amount of
collagen was quantified assuming 300 hydroxypro-
line residues per triple helix, i.e., 1 nmol Hyp
corresponds to 1 mg collagen. Collagen degra-
dation was expressed as the percentage of total
collagen released into the medium.
quantification of damaged collagen in beads
In beads, pre-cultured under control conditions
and then treated with IL-1b (0, 0.5, 5, or 20 ng/ml)
for 24 or 48 h, the percentage of damaged collagen,
indicative for degradation of the collagen network,
was determined as described elsewhere [34]. The
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assay is based on the fact that a-chymotrypsin
degrades damaged or collagenase-cleaved collagen
which is still covalently bound to the collagen
network, thereby releasing the resulting fragments
from the alginate beads. Intact triple helical
collagen is unaffected by a-chymotrypsin. Briefly,
proteoglycans were extracted from three beads
with 250 ml 4 m guanidinium-HCl in 50 mm Tris (pH
7.6) containing 10 mm CaCl2 and 10 mm BB94 (a
general MMP inhibitor, also known as Batimastat
or RS47,112, kindly supplied by Dr R. Martin,
Roche-Syntex, Palo Alto, CA [36]) at 4° C for 6 h.
After washing of the beads in the same solution
without guanidinium–HCl, damaged collagen was
digested by 0.25 mg/ml a-chymotrypsin (Sigma) in
250 ml/bead 50 mm Tris (pH 7.6) containing 10 mm
CaCl2 and 10 mm BB94 at 37° C for 3 h. Resulting
supernatant and beads were hydrolyzed and
subjected to amino acid analysis to determine
hydroxyproline using the OPA/FMOC derivatiza-
tion method described above. The percentage of
damaged collagen was calculated from the amount
of hydroxyproline released by a-chymotrypsin
divided by the total amount of collagen present in
the bead.
gelatin zymography of bead extracts and
culture medium
Beads were extracted in 50 mm Tris (pH 7.5),
containing 5 mm CaCl2, 0.15 m NaCl, 1 mm ZnCl2
and 0.1% Brij-35 for 16 h at 4° C. Extracts were
mixed with an equal volume of nonreducing
sodium dodecyl sulfate polyacrylamide gel electro-
phoresis (SDS-PAGE) sample buffer [125 mm Tris,
pH 6.8, 0.16% (v/v) glycerol, 4% (w/v) SDS, 0.01%
(w/v) bromophenol blue] and incubated for 1 h at
37° C, before electrophoresis. Culture medium
(50 ml) was dried under vacuum and the residue was
dissolved in nonreducing SDS-PAGE sample
buffer. Gelatin zymography [25, 37] was performed
under nonreducing conditions using a 10%
polyacrylamide gel containing 0.1% gelatin on a
ATTO electrophoresis system (ATTO, Tokyo,
Japan). Applied aliquot of bead extract to the gel
was comparable to 0.5 bead. Since the volume of
one bead is approximately 15 ml, and 10 beads were
cultured in 0.5 ml of medium, the equivalent of
35 ml medium ( 0 1/20 of beads plus medium) was
applied to the gel in order to compare the
concentration of MMPs in beads and medium. Gels
were washed in 50 mm Tris (pH 7.5) with 5 mm
CaCl2, 1 mm ZnCl2 and 2.5% Triton X-100 in which
the proMMPs and MMPs renature to active
enzymes [25,37]. Subsequently, gels were incubated
for 18 h in the same buffer without Triton (37° C).
ProMMPs and MMPs result in white lysis zones
after staining with Coomassie Brilliant Blue, due
to gelatin degradation.
mmp-activity measurements
Beads were extracted in 50 ml/bead 50 mm Tris
(pH 7.6), 5 mm CaCl2, 0.15 m NaCl, 1 mm ZnCl2 and
0.05% Brij-35 at 4° C at mild agitation for 72 h.
General MMP activity was measured in native
(unactivated) and APMA-activated (1 mm, 2 h,
37° C) extracts with fluorogenic substrate TNO211
(Dabcyl-Gaba–Pro–Gln–Gly–Leu–Glu(EDANS)–
Ala–Lys–NH2 (5 mm in buffer as above with 0.01%
Brij-35; further noted as incubation buffer) as
described earlier [38]. Catalytic efficiencies of
TNO211 for MMPs are (25° C): MMP-1, 18
.
103/M/s;
MMP-2, 230
.
103; MMP-3, 4
.
103; MMP-7, 9
.
103;
MMP-8, 29
.
103; MMP-9, 139
.
103; MMP-13, 550
.
103.
Measurements in bead extracts (45 ml) were
performed in a total volume of 180 ml in a black
round bottom microtiter plate and increase in
fluorescence (due to conversion of the substrate)
was quantified in a Cytofluor II fluorescence reader
(excitation filter: 360 nm, emission filter 490 nm;
Perseptive Biosystems).
The ability of APMA to activate MMP-tissue
inhibitor of metalloproteinases (TIMP) complexes
was investigated as follows: 5 nm MMP-3, 1 nm
MMP-13 (both generous gifts from Dr P. Mitchell,
Pfizer Inc., Groton, CT, U.S.A.) and 5 nm MMP-8
(kindly supplied by Dr G. Murphy, Strangeways
Labs, Cambridge, U.K.) were incubated with
equimolar amounts of TIMP-1 (from Dr G. Murphy,
Strangeways Labs, Cambridge, U.K.) in incubation
buffer at 37° C for 2 h. This resulted in 100%
inhibition of MMP activity. Thereafter, MMP-
TIMP complexes were incubated with(out) 1 mm
APMA for 2 h at 37° C. Resulting MMP-activity
was measured by the addition of 2 mm fluorogenic
substrate TNO211 (see above).
apma activation of il-1b stimulated beads
Alginate beads (cultured for 2 weeks and
stimulated with 20 ng/ml IL-1b for 48 h) were
incubated with 1 mm APMA at 37° C for 2 h in
incubation buffer (200 ml/bead, 50 mm Tris pH 7.6,
5 mm CaCl2, 0.15 m NaCl, 1 mm ZnCl2 and 0.01%
Brij-35) to activate proMMPs. Controls contained
no APMA, or APMA in the presence of 10 mm BB94
[36]. After the activation step, the incubation
medium was saved (to determine GAG and
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collagen release) and 200 ml incubation buffer per
bead (containing 10 mm BB94 when added during
the APMA-activation step) was added to the beads.
Subsequently, the beads were incubated for
another 16 h at which point the percentage of
damaged collagen was quantified as described
above.
data analysis
Data are expressed as mean 2 s.d. from three
separate cultures. Assays were run at least in
duplicate. Student’s t-test was used for statistical
analysis: P Q 0.05 was considered as statistically
significant.
Results
il-1b induced release of gag and collagen into
the medium
Chondrocytes were cultured for 2 weeks under
control conditions. After 14 days, collagen and
proteoglycan levels in the beads remained con-
stant (approximately 22 and 30 mg/mg DNA,
respectively [28]). The chondrocytes were
stimulated with IL-1b (0.5–20 ng/ml) for 1 or 2 days,
and release of glycosaminoglycans (GAG, as a
measure for proteoglycans) and collagen
(measured as hydroxyproline after acid hydrolysis)
into the medium was followed. A time and IL-1b
dose-dependent release of GAG from the bead was
seen: at 5 ng/ml (0.3 nm) of IL-1b, already 24% of
GAG was released in the medium after 1 day. This
was increased to 70% after 2 days [Fig. 1(a)]. At the
highest concentration of IL-1b (20 ng/ml) almost all
GAGs were released after 48 h ( 0 80%). Spon-
taneous release was negligible: under control
conditions virtually no GAGs were found in the
medium. The data obtained for GAG release were
in contrast to the degradation of collagen: no
increase in collagen content of the medium could
be observed at increasing amounts of IL-1b after 1
or 2 days [Fig. 1(b)].
content of damaged collagen in the bead
Stimulation of MMP-activity by IL-1b does not
necessarily result in release of collagen into the
medium, i.e., degraded collagen may stay in the
matrix due to intermolecular cross-linking; after
2 weeks of culture, a considerable level of
collagen cross-links are present in the beads
[28, 29]. Therefore, the amount of a-chymotrypsin
degradable damaged collagen was quantified. By
this method, unwound collagen resulting from
proteolytic degradation is further cleaved by
a-chymotrypsin and released from the collagen
network, whereas triple helical collagen is
not degraded [34]. Beads stimulated with IL-1b
for 1 or 2 days revealed no increase in the
percentage of a-chymotrypsin-degradable collagen
[Fig. 1(c)].
Fig. 1. IL-1b induced matrix degradation by bovine chondrocytes in alginate. Chondrocytes were cultured for 2 weeks
under control conditions and subsequently stimulated with IL-1b (0, 0.5, 5 and 20 ng/ml) for (w) 24 or (W) 48 h.
Proteoglycan degradation [panel (a): percentage of GAGs released into the medium], collagen degradation [panel (b):
Hyp released], and the amount of damaged collagen in the bead [panel (c): the percentage of a-chymotrypsin degradable
collagen] were monitored as described in Method.
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Fig. 2. Gelatin zymography of bead extracts and medium.
Chondrocytes cultured in alginate for 2 weeks under
control conditions were subsequently stimulated with
IL-1b for 24 and 48 h. Beads extracts (a) and medium (b)
were applied to a 10% polyacrylamide gel containing
0.1% gelatin. IL-1b concentrations and are indicated at
the top of the gel; molecular weights shown on the left.
Lysis zone at 0 72 kDa is likely to correspond to
proMMP-2, and at 0 90 kDa to proMMP-9.
proMMP-2 and -9 ((80 kDa) may represent active
MMP-9 and the band at (60 kDa) may result from
the active from of MMP-2 [Fig. 2(a)].
In the medium from nonstimulated cultures, only
proMMP-2 is present and it is not induced by IL-1b
[Fig. 2(b)]. The stimulation of proMMP-9 synthesis
is comparable to that found in the bead extracts.
Since other (pro)MMPs are not present in the
culture medium, we conclude that besides
proMMP-2 and proMMP-9, the majority of the
MMPs synthesized by the chondrocyte upon IL-1b
treatment are retained in the bead.
mmp-activity in bead extracts; effect of
apma
For proteolytic cleavage of extracellular matrix,
proMMPs have to be activated after excretion. To
investigate whether the large increase in synthesis
of MMPs upon IL-1b stimulation [zymography Fig.
2(a)] results in net MMP-activity, extracts of
alginate beads were analyzed with a sensitive
activity assay with the fluorogenic MMP sub-
strate, TNO211 [38]. This substrate is rapidly
cleaved by all MMPs tested so far (MMP-1, -2, -3,
-7, -8, -9, and -13). No increase in MMP-activity was
observed after IL-1b stimulation up to 48 h at
20 ng/ml IL-1b. This seems to be in contrast to
zymography [Fig. 2(a)] which indicates the induc-
tion of a variety of MMPs. Therefore, it is most
probable that the lysis zones originate from
proMMPs or MMPs which are inactivated by
complexation with TIMPs. It is known however,
that induction of TIMP upon IL-1 treatment in
chondrocytes is absent [25, 51]. Such MMP/TIMP
complexes are known to dissociate in the denatur-
ing zymography buffer environment [40], resulting
in lysis zones corresponding to active MMPs in
zymography.
To investigate whether the lysis zones in
zymography belong to proMMPs, bead extracts
were activated with APMA. This resulted in a time
and IL-1b dose-dependent increase in MMP-ac-
tivity [Fig. 3(b)] measured with TNO211, consistent
with the relative increase in (pro)MMP-levels seen
in zymography [Fig. 2(a)]. MMP-activity in beads
exposed to 20 ng/ml IL-1b for 48 h was 15-fold
higher than that in controls beads (without IL-1b).
Addition of the selective MMP-inhibitors TIMP-1
(10 nm) or BB94 (10 nm) totally suppressed the
enzyme-activity (data not shown). The APMA-in-
duced elevation of MMP-activity was not due to
dissociation of MMP/TIMP complexes: APMA-
treatment in vitro of MMP-3/TIMP-1, MMP-8/
TIMP-1 or MMP-13/TIMP-1 complexes did not
il-1b induction of mmp production: gelatin
zymography
To rule out the possibility that IL-1b does not
lead to MMP synthesis by chondrocytes in the
alginate bead system, extracts or culture medium
from IL-1b treated alginate beads were subjected to
zymography. In the non-stimulated culture only
proMMP-2 (72 kDa) is observed in the beads and
the medium (Fig. 2). Treatment with IL-1b resulted
in a clear IL-1b dose- and time-dependent induction
of proMMP synthesis. In more detail, strong
induction of several lysis bands between 40 and
60 kDa [bead extracts, Fig. 2(a)] and at 0 90 kDa
(proMMP-9) was observed, whereas the level of
proMMP-2 was not or only marginally increased.
The 45–60 kDa bands are likely to correspond to
multiple forms of stromelysin (MMP-3) or the
collagenases MMP-1, -8 and -13 (different degrees
in glycosylation and autolysis of proMMP into
smaller forms [8, 9, 25, 39]). The lysis zone between
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result in active enzyme, when measured with
TNO211 (data not shown).
Therefore, the detected MMP-activity must
result from APMA-activated proMMPs, which
were not neutralized by free TIMPs in the bead.
Furthermore, the lysis zones seen in zymography
are most likely to correspond to proMMPs and not
active MMPs.
role of mmps in gag release after activation
by apma
Beads, treated for 1 day with 20 ng/ml IL-1b still
contain approximately 75% of the GAGs [Fig. 1(a)],
and high levels of proMMPs [Fig. 2(a)]. To examine
whether active MMPs (once activated) are able to
degrade proteoglycans, the beads were incubated
for 2 h (37° C) with 1 mm APMA to activate
proMMPs. In the absence of APMA, approximately
24% of the GAGs (still present in the bead after
IL-1b-stimulation) is released, most likely resulting
from aggrecanase-activity [Fig. 4(a)]. When treated
with APMA, the GAG release was increased to
31% (P Q 0.05). This additional degradation of
aggrecan indicates that activated MMPs may play
a significantly role in proteoglycan degradation.
No significant effect of APMA on proteoglycan
release was seen using beads which were not
stimulated with IL-1b [Fig. 4(a)].
effect of activation of prommps on collagen
degradation, and damaged collagen content
in the bead
To monitor the effect of proMMP activation on
collagen degradation, IL-1 stimulated beads (2
days, 20 ng/ml) were incubated with APMA. This
resulted in a threefold increase in collagen release
from the bead in as little as 2 h in comparison with
non-APMA activated beads [Fig. 4(b)]. This
demonstrates that the APMA-mediated increase in
MMP-activity as determined with the fluorogenic
activity assay [Fig. 3(b)] indeed results in rapid
degradation of the collagen network. In non-IL-1b
stimulated beads APMA treatment caused no
increase in collagen release [Fig. 4(b)], indicating
that a negligible amount of proMMPs are present
in the control situation. The collagen release after
IL-1 and APMA-activation could be totally
abolished by the MMP-inhibitor BB94 [10 mm; Fig.
4(b)]. Similar findings are shown for the fraction of
damaged collagen in IL-1 stimulated beads after
exposure to APMA: an increase upon APMA-acti-
vation and blocking of degradation by BB94 down
to basal levels of damaged collagen [IL-1, no
APMA; Fig. 4(c)]. Hydroxyproline release [Fig.
4(b)] together with the amount of damaged
collagen [Fig. 4(c)] indicate that after APMA
activation the IL-1 induced MMPs are able to
rapidly degrade the collagen network.
Fig. 3. MMP-activities in extracts of IL-1b stimulated beads. Chondrocytes cultured in alginate for 2 weeks under
control conditions were subsequently stimulated with IL-1b (0, 0.5, 5, and 20 ng/ml) for 24 and 48 h. MMP-activity in
the extracts with and without prior activation by APMA was determined using the fluorogenic MMP substrate
TNO211, see Method for details.(a) Non-activated; (b) APMA activated; (w) 24 h; (W) 48 h.
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Fig. 4. Effect of proMMP-activation by APMA on proteoglycan (a) and collagen (b) degradation, and the percentage
of damaged collagen in the bead (c). Chondrocytes containing alginate beads were cultured for 2 weeks and
subsequently stimulated with IL-1b for 24 h (proteoglycans) or 48 h (collagen), followed by an incubation for 2 h in the
presence of 1 mm APMA. The percentage of damaged collagen in the bead (a-chymotrypsin degradable collagen) was
determined after another incubation of 16 h in the absence of APMA. * Significantly different: P Q 0.05 (Student’s
t-test).
Discussion
The alginate culture system was previously
shown to be an excellent model to study matrix
synthesis by chondrocytes [28, 29, 41]. In the
present study we have been able to apply
established methodologies such as degradation of
proteoglycans, collagen release, and quantification
of damaged collagen content in this model system
to study the direct effect of IL-1 on matrix
degradation by chondrocytes.
Topographical differences in susceptibility of
chondrocytes to IL-1 in cartilage explants [42] have
been eliminated in the alginate culture system for
all beads contain an identical cell population. As
such, more reproducible results can be expected
with the alginate culture system than with
articular cartilage explants.
Upon stimulation with IL-1b extensive proteo-
glycan depletion occurred: at only 5 ng/ml more
than 70% of the GAGs was released within 2 days.
This in good agreement with the rapid proteogly-
can degradation observed with cartilage explants
[20, 21, 23, 24, 43–45]. The IL-1 mediated release of
proteoglycans was attributed to ‘aggrecanase’
based on the release of specific aggrecan fragments
[17, 43]. In our studies, we show that APMA-treat-
ment of IL-1b stimulated beads resulted in a nearly
30% increase of GAG release. This suggests that
MMPs (when activated) can contribute to proteo-
glycan degradation in a cartilage-like extracellu-
lar matrix. This corroborates the findings that
MMPs can degrade isolated aggrecan [14, 19, 46–
49] and implies that MMPs can play a role in
proteoglycan turnover in vivo. To which extent
MMPs are involved in aggrecan degradation in
cartilage remains unknown until quantitative
methods become available to monitor both the
neoepitopes generated by MMPs and aggrecanase.
In our model system, after activation of proMMPs,
25% of the total GAG release was likely to result
from MMP-activity. This suggests that in vivo,
where only a small fraction of the MMPs is
activated, their involvement in aggrecan degra-
dation will be small compared to aggrecanase-me-
diated turnover.
No increase in MMP-activity in alginate beads
was detected after 2 days of stimulation by
20 ng/ml IL-1b. Therefore, aggrecan degradation
can not be related to MMP-activity, which
corroborates recent findings that ‘aggrecanase’ is
not a known MMP [50]. The absence of MMP-ac-
tivity in the bead corresponded to the absence of
hydroxyproline release into the medium (treatment
with 20 ng/ml IL-1b, 2 days). As local degradation
of the collagen network in the bead does not result
per se in release of collagen fragments into the
medium, the amount of degraded collagen in the
bead was quantified. However, also no significant
increase in degraded collagen was observed which
supports the finding that no active MMPs are
present after stimulation with IL-1b. Clearly, this
was not due to a lack of MMP synthesis:
upregulation of MMP synthesis was observed in
zymography as new lysis zones which are likely
to correspond to MMP-1, -3, -8 or -13 (45–60 kDa)
and MMP-9 ( 0 90 kDa), whereas MMP-2 ex-
pression was not or only marginally induced. In
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zymography, the sensitivity to detect the gelati-
nases MMP-2 and MMP-9 is about 100-fold higher
than for other MMPs [49, 51]. Since the intensity of
the lysis bands in the region corresponding to the
molecular weights of MMP-1, -3, -8 and -13 were
comparable to those of the gelatinases, our
findings indicate that gelatinases constitute 10%
or less of the total MMPs.
The excreted MMPs upon IL-1b treatment were
still in the latent form, as concluded from
experiments where APMA was used to activate
proMMPs: the collagen matrix in the alginate bead
rapidly deteriorated which was paralleled by an
increase in MMP-activity measured with the
fluorogenic substrate TNO211. Together with the
findings that the MMP-inhibitor BB94 inhibited
enzyme-activity and collagen degradation, this
suggests that the latent MMPs induced by IL-1 are
able to rapidly degrade the collagen matrix once
activated. This presence of active MMPs after
APMA treatment in combination with the obser-
vation that APMA did not activate MMP-TIMP
complexes, indicates that the increase in enzyme-
activity must be a result from an excess of active
MMPs over TIMPs. Hence, our enzyme activity
data are consistent with immunological findings
that MMP/TIMP ratios in cartilage are increased
upon IL-1 treatment [25, 42, 52].
Our collagen degradation data correspond to
recent findings from others with bovine nasal
cartilage explants: collagen degradation was only
found after exposure to high amounts of IL-1 for 3
weeks [20, 23, 24]. The late onset of degradation in
nasal explants was putatively attributed to a
change in chondrocyte phenotype during the
culture period (3 weeks) [20]. Another possible
explanation is that prolonged stimulation of
cartilage explants with IL-1 results in a accumu-
lation of latent MMPs, which may lead to
autoactivation of proMMPs due to high local
concentrations as described for proMMP-2 [53].
Taken together, investigations by others and the
present study indicate that IL-1 effectively in-
creases proMMP synthesis and that activation of
these proMMPs requires other factors than IL-1 for
collagen degradation of cartilage to occur.
The actual presence of active MMPs in cartilage
from arthritides was shown immunohistochemi-
cally: MMP-generated neoepitopes in collagen and
aggrecan were observed [54–58]. This implies the
presence of MMP-activating factors in cartilage in
vivo which may include catabolic cytokines and
activators of proMMPs. Several enzymes have
been suggested to play a role in proMMP
activation. Plasmin [59,60], kallikrein [61], mast
cell proteinases [62] activate proMMPs in vitro,
but are not produced by chondrocytes. Elevated
levels of the plasminogen activator/plasmin system
and kallikrein have been found in synovial fluid
from arthritis patients [63, 64]. Besides proteolytic
activation of latent MMPs, other mediators can be
involved like hypochloric acid produced by
neutrophils that is able to activate proMMP-8 and
-9 [65, 66]. In addition, a decrease in pH is known
to activate proMMP-3 [67, 68] and may be local
phenomenon, but the involvement in cartilage
degradation is still unknown.
In this model, we have shown that a pool of
proMMPs can be activated by the artificial
activator APMA resulting in matrix degradation.
For investigation of putative proMMP activators,
the alginate culture system for chondrocytes seems
a suitable and convenient model, and can be
helpful in screening drugs for their ability to
counteract induced matrix degradation. In con-
trast to cartilage explants, interfering constituents
from synovial fluid which may confound the direct
effect of a cytokine on matrix degradation are
lacking in alginate beads.
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